期刊文献+

吡柔比星不同膀胱灌注方法预防膀胱癌术后复发及不良反应的临床研究 被引量:4

Clinical Study of Intravesical Instillation of Pirarubicin by Two Methods on Preventing Recurrence of Bladder Cancer and Adverse Reaction
原文传递
导出
摘要 目的比较吡柔比星(THP)两种膀胱内灌注方法预防浅表性膀胱癌术后复发的有效性及安全性。方法将80例经尿道膀胱癌电切术后浅表性膀胱癌患者随机分为2组,均于术后1周开始灌注,每次THP灌注剂量40 mg,每周灌注1次,连续8周,再改为每月灌注1次,至术后1年。灌注前实验组THP用蒸馏水80 mL稀释,对照组THP用蒸馏水40 mL稀释。结果全部病例均获随访,时间为2年,2组复发率比较差异无统计学意义(P>0.05),不良反应发生率实验组显著低于对照组(P<0.05)。结论 THP 40 mg+蒸馏水80 mL膀胱灌注方法可以明显降低肿瘤患者术后吡柔比星膀胱灌注的不良反应,值得推荐。 OBJECTIVE To compare the effect and safety of intravesical instillation of pirarubicin by two methods on preventing recurrence of superficial bladder cancer. METHODS All of 80 cases with bladder cancer after transurethral bladder tumor resection (TUR-BT) were divided into two groups in random. All cases accepted intravesical instillation of pirarubicin 40 mg in one week after operation, once a week for 8 weeks, then once a month for 1 year. The test group used THP 40 mg+ distilled water 80 mL, the control group used THP 40 mg+distilled water 40 mL. RESULTS All cases were followed-up 2 years after operation, the recurrence rate was no statistical significance between two groups(P〉0.05), but the incidence rates of the adverse reaction in test group was significantly lower than control group(P〈0.05). CONCLUSION Intravesical instillation of THP 40 mg+distilled water 80 mL can obviously reduce the adverse reaction, and it is worth recommending.
出处 《中国现代应用药学》 CAS CSCD 2012年第6期557-559,共3页 Chinese Journal of Modern Applied Pharmacy
关键词 浅表性膀胱癌 膀胱灌注 吡柔比星 superficial bladder cancer intravesical pirarubicin
  • 相关文献

参考文献5

二级参考文献33

  • 1陈嵘,徐月敏,乔勇,张心如,金三宝.吡柔比星灌注预防复发性膀胱癌术后复发的疗效观察[J].上海医学,2002,25(z1):91-92. 被引量:1
  • 2杨德安,李慎勤.表浅型膀胱肿瘤术后复发的预防[J].临床泌尿外科杂志,1996,11(2):123-125. 被引量:12
  • 3田溪泉,邢念增,王勇,李建兴.早期吡柔比星膀胱内灌注预防膀胱癌术后复发[J].临床泌尿外科杂志,2006,21(1):4-6. 被引量:35
  • 4朱育春,魏强,李虹,杨宇如,卢一平,何凡,贺军,梅建东.TUR-BT术后吡柔比星与羟基喜树碱BCG膀胱灌注的疗效比较[J].中国肿瘤临床,2006,33(21):1254-1255. 被引量:12
  • 5荻原雅彦 相川键 等.不同药物膀胱灌注预防浅表性膀胱癌复发的研究[J].临床泌尿,1994,8:603-608.
  • 6Lamm DL.Prophylaxis for recurrent transitional cell carcinoma[J].Urology,1991,37(Suppl 5):21.
  • 7Nakagawa S,Kojima M,Takada H,et al.Short-duration bladder instillation therapy with pirarubicin for superficial bladder tumor based on pharmacodynamic study[J].Gan To Kagaku Ryoho,1992,19(11):1873.
  • 8Kobayashi M,Sugaya Y,Yuzawa M,et al.Appropriate intravesical retention time of pirarubicin concentration based on its level in tumor tissue,anti-tumor effect and side effect in intravesical instillation therapy for bladder tumor[J].Gan To Kagaku Ryoho,1998,25(11):1771.
  • 9Okamura K,Ono Y,Kinukawa T,et al.Randomized study of single early instillation of (2″R)-4′-O-tetrahy-dropyranyl-doxorubicin for a single superficial bladder carcinoma[J].Cancer,2002,94(9):2363.
  • 10]Kuroda K,Lshii N,Fukasawa K,et al.Short term intravesical instillation of pirarubicin (THP) in prophylaticc treatment after transurethral resection of superficial bladder tumor[J].I Hinyokika Kiyo,1998,44(8):547.

共引文献66

同被引文献45

引证文献4

二级引证文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部